SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism

Rheumatoid Arthritis Clinical Trial

— COVIRIC  

Official title:

Study of the Viral Load and Humoral and Cellular B and T Responses in Patients With Rheumatoid Arthritis and Spondyloarthritis Under Immunosuppressive Treatments

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04584541
• Other study ID #: APHP200598
• Status: Terminated
• Phase: N/A
• Start date: June 11, 2020
• Est. completion date: February 21, 2022

Study information

• Verified date: May 2022
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess whether immunosuppressive therapies used by patients with chronic inflammatory rheumatic diseases have an impact on the viral load and the humoral and cellular responses during viral infection with SarSCoV2, compared to members of their family cluster infected with the same viral strain.

Description:

Rheumatoid arthritis (RA) and spondyloarthritis (SPA) are the two most common chronic inflammatory rheumatic diseases, with a prevalence of 0.5-1% for RA and about 0.35% for SPA. Many studies have described an increased risk of serious infectious diseases directly associated with increased morbidity and mortality among those patients. This increased risk (frequency and severity) results from the disease itself, especially if the rheumatism is not controlled with high disease activity, but also due to the immunosuppressive treatments used to treat these patients. The risk of infection is measured by the Incidence Rate (IR) corresponding to the number of events (infections) per 100 patients/years of follow-up. This risk is accepted as comparable between patients with SpA or RA and ranges from 22 to 34/100 patient-years, depending on the studies, for patients on biologics. The risk of infection is higher for patients on biotherapy than for patients on Disease Modifying Anti-Rheumatic Drugs (DMARDs - mainly Methotrexate) and the combination of corticosteroid therapy with the biotherapies further increases this risk of infection. Lung and upper respiratory tract infections are the most common infections observed under biotherapy. The risk of infection may be different depending on the biotherapy considered. Moreover, the vaccine response is also highly variable depending on the biotherapy, treatments with Rituximab, methotrexate and abatacept being those interfering the most with the quality of the vaccine response. The working hypothesis is therefore that certain immunosuppressive treatments used in these inflammatory rheumatic conditions may interfere with the humoral and/or cellular anti-SarS-Cov-2 immune response.

Since December 2019, the first SARS-Cov-2 (Severe acute respiratory coronavirus 2 syndrome) infections have been described in Wuhan province in China. In April 2020, 1,824,950 people were officially infected in 193 countries worldwide with 112,510 deaths reported (Agence France Presse and World Health Organization; 13 April 2020). To date, the investigators have a limited amount of data concerning the seroconversion of infected subjects, the protective or non-protective nature of the specific antibodies generated, and the duration of protection. No data have been generated on the specific B and T responses of SarS-Cov-2. In addition, the few available data in the literature on SarS-Cov-2 only concern the general population, not exposed to immunosuppressive treatments.

However, major questions are currently unanswered for patients on immunosuppressive treatments: Are they excreting the virus for longer periods of time? How long can this viral excretion be measured in the upper airways and in the stool? Do they develop a humoral and cellular immune response similar to the general population? Accurate knowledge of the dynamics of the virus and the immune response induced will be essential for the development of strategies for antiviral treatment, vaccination protocols and for the epidemiological control of Covid-19.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 150
• Est. completion date: February 21, 2022
• Est. primary completion date: February 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

cases

• Patient with spondyloarthritis fulfilling the ASAS criteria

• Patients with rheumatoid arthritis fulfilling the ACR/EULAR criteria and

• Immunosuppressive therapy: Methotrexate, leflunomide, anti-TNF, Anti-IL6R, abatacept, rituximab, Jak inhibitors (tofacitinib or baricitinib) And

• infected with the SarS-Cov-2 (positive PCR and/or serology and/or CT-scan)

Controls:

• Family cluster member confined to the same location as the index subject

• Infected with the SarS-Cov-2 (positive PCR and/or serology and/or CT-scan)

Exclusion Criteria:

cases and controls

• Pregnant woman

• Breastfeeding woman

• Immunosuppressed subject for members of the familiar cluster of the index subject

• Patient with no social security

• Patients whose freedom is limited by the judicial or administrative authority

• Patients under legal protection

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• COVID-19
• Covid19
• Rheumatoid Arthritis
• Spondylarthritis
• Spondyloarthritis

Intervention

Biological:
• blood tests
Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)
• Nasopharyngeal swabs
SarS-Cov-2 viral load assessment
• Stools
SarS-Cov-2 viral load assessment

Locations

Country	Name	City	State
France	Cochin hospital	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs	Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA	up to Day 30
Primary	Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs	Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA	between Day 30 and Day 90
Primary	Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood		up to Day 30
Primary	Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood		between Day 30 and Day 90
Primary	Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood		6 Months
Primary	Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood		12 Months
Primary	Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood		24 Months
Primary	Isolation and characterization of B and T lymphocytes in blood		up to Day 30
Primary	Isolation and characterization of B and T lymphocytes in blood		between Day 30 and Day 90
Primary	Isolation and characterization of B and T lymphocytes in blood		6 Months
Primary	Isolation and characterization of B and T lymphocytes in blood		12 Months
Primary	Isolation and characterization of B and T lymphocytes in blood		24 Months